Baker Bros Reveals New Stake in Aquinox Pharmaceuticals (AQXP)

In a new filing with the SEC, Julian Baker and Felix Baker’s Baker Bros. Advisors revealed new stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP). In Aquinox Pharmaceuticals, Baker Bros currently owns a total of 1.2 million shares, which make the holding equal to 12.1% of the common stock.

Pharmacyclics, Inc. (NASDAQ:PCYC)

Aquinox Pharmaceuticals, Inc (NASDAQ:AQXP) is a clinical-stage pharmaceutical company which discovers and develops novel drugs candidates for the treatment of inflammation and cancer.

Last month, the company closed its initial public offering of approximately 4.8 million shares at an offer price of $11.0 per share, which included 630,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. The total offering price is an estimated $53.1 million, excluding underwriting discounts, estimated expenses and commissions. This month, Zacks initiated coverage on Aquinox with a ‘Hold’ rating. Another analyst, Cowen and Company, initiated coverage on Aquinox Pharmaceuticals, Inc (NASDAQ:AQXP) with an ‘outperform’ recommendation at a target price of $30.0 per share.

Baker Bros Advisors, LLC, is located in New York and is a privately owned hedge fund. The fund has an equity portfolio of $7.1 billion, concentrated in the Healthcare sector. It was founded in the year 2000 by Felix Baker and Julian Baker. Dr. Felix J. Baker, who holds a B.S. in Biology and Ph.D in Immunology from Standford University, serves as the Managing Member of the fund. Co-founder, Julian C. Baker holds an A.B. Magna Cum Laude from the Harvard University, also serves as the managing member of the fund.

Baker Bros Advisors has been active until last month, reporting new and tweaked stakes in several companies. Last month, the fund upped positions in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to 20.5 million shares and in Synageva Biopharma Corp (NASDAQ:TRMS) to 8.2 million shares. In January, Baker Bros disclosed holding 13.8 million shares in Genomic Health, Inc. (NASDAQ:GHDX) and 5.3 million shares in Celsus Therapeutics PLC (ADR) (OTCMKTS:CLSXD).

According to the fund’s latest 13F, top holdings of Baker Bros, as at the end of last year, were Pharmacyclics Inc (NASDAQ:PCYC), with a stake valued in excess of $922.3 million, followed by Seattle Genetic Inc. (NASDAQ:SGEN), of which it held around 20.7 million shares worth $827.2 million, and Incyte Corp (NASDAQ:INCY), in which it owned 14.8 million shares valued at more than $749.9 million.

Disclosure: none

Recommended Reading:

Southpoint Capital Advisors Ups Interest in Nexstar Broadcasting Group, Inc. (NXST)

Deerfield Management Boosts Stake In Insmed Incorporated (INSM)

Adage Capital and Maverick Capital are Bullish on Castlight Health Inc (CSLT)

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!